Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244471 | 0.83 | KDM4E (0.47) | KMT2AMEN1POLBSCN3ALMNA | |
| SCHEMBL8244222 | 0.83 | NPC1 (0.57) | KMT2AMEN1SCN3ASMN1; SMN2L3MBTL1 | |
| SCHEMBL13007613 | 0.80 | RXFP1 (0.45) | KMT2AMEN1SCN3ALMNASMN1; SMN2 | |
| SCHEMBL1863465 | 0.78 | SLC40A1 (0.51) | KMT2AMEN1 | |
| SCHEMBL27749772 | 0.78 | KDM4E (0.43) | KMT2AMEN1SCN3ALMNASMN1; SMN2 | |
| SCHEMBL1856352 | 0.76 | KDM4E (0.53) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11959669 | 0.73 | MAPK1 (0.48) | KMT2AMEN1SCN3ALMNAMAPK1 | |
| SCHEMBL1868493 | 0.73 | NPC1 (0.61) | KMT2AMEN1SCN3ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1858135 | 0.73 | KMT2A (0.57) | KMT2AMEN1SCN3A | |
| SCHEMBL11959664 | 0.73 | POLB (0.47) | KMT2AMEN1POLBSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492403-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492403-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492403-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| US-8357702-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357702-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357702-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| WO-2007030618-A2 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120308606-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPV2, TRPV3 | KMT2A 3438/4885MEN1 4811/4885POLB 4449/4885 |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | TRPV1, TRPV2, TRPV3 | KMT2A 3438/4885MEN1 4811/4885POLB 4449/4885 |
| US-20130131109-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPV2, TRPV3 | KMT2A 3438/4885MEN1 4811/4885POLB 4449/4885 |
| US-20110112156-A1 | Bicyclic Derivatives as Modulators of Voltage Gated ION Channels | TRPV1, TRPV2, TRPV3 | KMT2A 3438/4885MEN1 4811/4885POLB 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.